MedPath

Ibrexafungerp

Generic Name
Ibrexafungerp
Brand Names
Brexafemme
Drug Type
Small Molecule
Chemical Formula
C44H67N5O4
CAS Number
1207753-03-4
Unique Ingredient Identifier
A92JFM5XNU
Background

Ibrexafungerp, also known as SCY-078 or MK-3118, is a novel enfumafungin derivative oral triterpene antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as a vaginal yeast infection. It was developed out of a need to treat fungal infections that may have become resistant to echinocandins or azole antifungals. Ibrexafungerp is orally bioavailable compared to the echinocandins caspofungin, micafungin, and anidulafungin; which can only be administered parenterally. Similar to echinocandins, ibrexafungerp targets the fungal β-1,3-glucan synthase, which is not present in humans, limiting the chance of renal or hepatic toxicity.

Ibrexafungerp was granted FDA approval on 1 June 2021.

Indication

Ibrexafungerp is indicated in the treatment of vulvovaginal candidiasis in post-menarchal patients. It is also indicated for the reduction in the incidence of recurrent vulvovaginal candidiasis.

Associated Conditions
Recurrent Vulvovaginal Candidiasis, Vulvovaginal Candidiasis
Clinical Trials
Related News

FDA Approves Blujepa, First New Class of Oral Antibiotic for UTIs in Nearly 30 Years

• GSK's Blujepa (gepotidacin) has received FDA approval for treating uncomplicated urinary tract infections, marking the first new class of oral antibiotics for UTIs in nearly three decades. • The novel triazaacenaphthylene antibiotic demonstrated non-inferiority or superiority to nitrofurantoin in clinical trials, offering a new treatment option amid rising antibiotic resistance concerns. • Blujepa works through a unique dual-enzyme inhibition mechanism that may reduce the potential for resistance development, with commercial availability expected in the second half of 2025.

Incyte Reports Strong 2024 Growth with $4.2B Revenue, Outlines Ambitious 2025 Pipeline Milestones

• Incyte achieved total revenues of $4.2 billion in 2024, marking a 15% year-over-year growth, driven by strong performance of Jakafi ($2.8B) and Opzelura ($508M). • The company anticipates four new product launches in 2025, including Niktimvo for chronic GVHD and expanded indications for existing therapies in atopic dermatitis and lymphoma. • Incyte's R&D pipeline shows significant advancement with plans for four pivotal study readouts, three Phase 3 study initiations, and seven proof-of-concept study results expected in 2025.

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247 for Invasive Fungal Infections

SCYNEXIS, Inc. has commenced dosing in a Phase 1 trial for SCY-247, a second-generation antifungal aimed at treating severe invasive fungal infections. The trial focuses on safety, tolerability, and pharmacokinetics in healthy subjects.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy